Base de dados : MEDLINE
Pesquisa : E01.370.225.500.195.107.595 [Categoria DeCS]
Referências encontradas : 52353 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 5236 ir para página                         

  1 / 52353 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29505517
[Au] Autor:Abulimiti A; Husaiyin A; Sailai Y
[Ad] Endereço:Department of General Surgery, First Affiliated Hospital of Xinjiang Medical University, Urimqi, China.
[Ti] Título:Evaluation of HVHF for the treatment of severe acute pancreatitis accompanying MODS.
[So] Source:Medicine (Baltimore);97(1):e9417, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Systemic inflammatory response syndrome (SIRS) prevention is key to severe acute pancreatitis (SAP) treatment and the assessment of high-volume hemofiltration (HVHF) for treating SAP accompanying multiple organ dysfunction syndromes.In this prospective controlled study, 40 SAP patients were divided into 2 groups: control (n = 22, treated with fasting, decompression, and intravenous somatostatin) and HVHF (n = 18, HVHF administration in addition to the treatment in the control group) groups; and were assessed for serum and urine amylase, WBC, C-reactive protein (CRP), and hepatic and renal functions. Vital signs and abdominal symptoms were recorded, and complications and mortality were analyzed.APACHE II scores in the HVHF group were significantly lower than in the control group at 3 and 7 days (6.3 ±â€Š1.7 vs 9.2 ±â€Š2.1 and 3.3 ±â€Š0.8 vs 6.2 ±â€Š1.7, respectively). Compared with controls, serum, and urine amylase, WBC, CRP, and organ functions significantly improved after HVHF treatment. Meanwhile, mortality (16.7% vs 31.8%) and complication (11.1% vs 40.9%) rates were significantly reduced.The other clinical parameters were significantly ameliorated by HVHF. HVHF rapidly reduces abdominal symptoms and improves prognosis, reducing mortality in SAP patients; and is likely through systemic inflammatory response syndrome attenuation in the early disease stage.
[Mh] Termos MeSH primário: Hemofiltração/estatística & dados numéricos
Insuficiência de Múltiplos Órgãos/etiologia
Pancreatite/terapia
[Mh] Termos MeSH secundário: APACHE
Adulto
Idoso
Amilases/sangue
Amilases/urina
Nitrogênio da Ureia Sanguínea
Proteína C-Reativa/metabolismo
Feminino
Seres Humanos
Contagem de Leucócitos
Testes de Função Hepática
Masculino
Meia-Idade
Insuficiência de Múltiplos Órgãos/sangue
Insuficiência de Múltiplos Órgãos/urina
Pancreatite/sangue
Pancreatite/complicações
Pancreatite/urina
Estudos Prospectivos
[Pt] Tipo de publicação:CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
9007-41-4 (C-Reactive Protein); EC 3.2.1.- (Amylases)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009417


  2 / 52353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29484748
[Au] Autor:Peurala E; Tuominen M; Löyttyniemi E; Syrjänen S; Rautava J
[Ad] Endereço:Department of Oral Pathology and Oral Radiology, Institute of Dentistry, Faculty of Medicine, University of Turku, Turku, Finland.
[Ti] Título:Eosinophilia is a favorable prognostic marker for oral cavity and lip squamous cell carcinoma.
[So] Source:APMIS;126(3):201-207, 2018 Mar.
[Is] ISSN:1600-0463
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:Eosinophils are frequently encountered with squamous cell carcinomas (SCC) and it has been proposed that tumor-associated tissue eosinophilia (TATE) could be of prognostic significance in oral SCC. The aim was to evaluate TATE in 83 oral cavity and 16 lip SCCs as well as the best possible use of TATE as a prognostic marker. The number of eosinophils was counted per high power fields (HPF, ×400) in three different representative areas of the tumor and its stroma. The degree of TATE was analyzed in relation to clinicopathological features of tumors and patients' survival (follow-up mean 40.7 months) using Fisher's exact test. TATE was detected in 58 (70%) oral and 8 (50%) lip SCC samples. The median number of eosinophils between oral and lip SCC was different (p = 0.028) but TATE was similar per HPF (p = 0.085). Totally, 6% of lip and 21% of oral SCC patients died during the follow-up. The patients with the higher TATE had significantly better survival than the patients with the lower TATE (p = 0.0136). The best cut-off value predicting the survival was 4 eosinophils/HPF. TATE is a prognostic marker for oral and lip SCC: more than 4 eosinophils/HPF may predict more favorable prognosis.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/patologia
Eosinofilia/patologia
Eosinófilos/patologia
Neoplasias Labiais/patologia
Lábio/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Consumo de Bebidas Alcoólicas/efeitos adversos
Biomarcadores Tumorais/metabolismo
Carcinoma de Células Escamosas/mortalidade
Intervalo Livre de Doença
Eosinófilos/citologia
Feminino
Seres Humanos
Contagem de Leucócitos
Neoplasias Labiais/mortalidade
Masculino
Meia-Idade
Estudos Retrospectivos
Fumar/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180228
[St] Status:MEDLINE
[do] DOI:10.1111/apm.12809


  3 / 52353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29320813
[Au] Autor:Muñoz-Carrillo JL; Muñoz-López JL; Muñoz-Escobedo JJ; Maldonado-Tapia C; Gutiérrez-Coronado O; Contreras-Cordero JF; Moreno-García MA
[Ad] Endereço:Laboratory of Cell Biology and Microbiology, Academic Unit of Biological Sciences, Autonomous University of Zacatecas, Zacatecas, Zacatecas, México.
[Ti] Título:Therapeutic Effects of Resiniferatoxin Related with Immunological Responses for Intestinal Inflammation in Trichinellosis.
[So] Source:Korean J Parasitol;55(6):587-599, 2017 Dec.
[Is] ISSN:1738-0006
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:The immune response against Trichinella spiralis at the intestinal level depends on the CD4+ T cells, which can both suppress or promote the inflammatory response through the synthesis of diverse cytokines. During the intestinal phase, the immune response is mixed (Th1/Th2) with the initial predominance of the Th1 response and the subsequent domination of Th2 response, which favor the development of intestinal pathology. In this context, the glucocorticoids (GC) are the pharmacotherapy for the intestinal inflammatory response in trichinellosis. However, its therapeutic use is limited, since studies have shown that treatment with GC suppresses the host immune system, favoring T. spiralis infection. In the search for novel pharmacological strategies that inhibit the Th1 immune response (proinflammatory) and assist the host against T. spiralis infection, recent studies showed that resiniferatoxin (RTX) had anti-inflammatory activity, which decreased the serum levels of IL-12, INF-γ, IL-1ß, TNF-α, NO, and PGE2, as well the number of eosinophils in the blood, associated with decreased intestinal pathology and muscle parasite burden. These researches demonstrate that RTX is capable to inhibit the production of Th1 cytokines, contributing to the defense against T. spiralis infection, which places it as a new potential drug modulator of the immune response.
[Mh] Termos MeSH primário: Diterpenos/farmacologia
Diterpenos/uso terapêutico
Enteropatias Parasitárias/tratamento farmacológico
Enteropatias Parasitárias/imunologia
Intestinos/imunologia
Triquinelose/tratamento farmacológico
Triquinelose/imunologia
[Mh] Termos MeSH secundário: Animais
Linfócitos T CD4-Positivos/imunologia
Citocinas/metabolismo
Eosinófilos/imunologia
Seres Humanos
Mediadores da Inflamação/metabolismo
Contagem de Leucócitos
Células Th1/imunologia
Células Th2/imunologia
Trichinella spiralis/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cytokines); 0 (Diterpenes); 0 (Inflammation Mediators); A5O6P1UL4I (resiniferatoxin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.3347/kjp.2017.55.6.587


  4 / 52353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29287882
[Au] Autor:Cavel O; Tauman R; Simsolo E; Yafit D; Reindorf-Kfir E; Wasserzug O; Unger O; Handzel O; Fishman G; Oestreicher-Kedem Y; DeRowe A
[Ad] Endereço:Pediatric ENT Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Otolaryngology, Head & Neck and Maxillofacial Surgery, Tel Aviv Sourasky Medical Center, Affiliated to the Sack
[Ti] Título:Changes in the epidemiology and clinical features of acute mastoiditis following the introduction of the pneumococcal conjugate vaccine.
[So] Source:Int J Pediatr Otorhinolaryngol;104:54-57, 2018 Jan.
[Is] ISSN:1872-8464
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Seven years after the introduction of the pneumococcal conjugate vaccines (PCV) in Israel, its effect on the incidence and severity of episodes of acute mastoiditis (AM) remains unclear. The primary objective of this study was to determine the incidence of AM and describe its clinical features in children during the years that followed the introduction of the PCV13 in comparison with the pre-PCV period. METHODS: Included in this retrospective comparative case series were all pediatric patients diagnosed with AM between Jan. 2007 and Dec. 2015 in one tertiary medical center. The patients were divided into 3 groups: pre-PCV, post-PCV7 (July 2009 through Dec. 2010) and post-PCV13 (Jan. 2011 through Dec. 2015). The patients' medical records were reviewed, and data on age at presentation, gender, presenting signs, bacterial ear cultures, hospitalization course, complications, surgical interventions, inflammatory response and outcome were retrieved and compared between the groups. Comparison was made between the pre-PCV and the post-PCV13 groups. RESULTS: 216 children were identified for analysis, 80 children in the pre-PCV period, 31 in the post-PCV7 period and 105 in the post-PCV13 period. Their mean age was 2.6 years. The number of AM cases per 1000 visits at the emergency room decreased by 46% in the post-PCV13 period compared to the pre-PCV period. There was no difference in the rate of AM between the post-PCV7 and post-PCV13 periods. No differences were found in age, gender, hospitalization length, C-reactive protein level, white blood cell count, rate of surgical interventions (mastoidectomy and incision and drainage) and rate of complications between the 3 groups. CONCLUSION: The incidence of AM was lower in the post-PCV13 period compared to the pre-PCV period. The rate of AM complications, however, has not changed, nor has the number of mastoidectomies.
[Mh] Termos MeSH primário: Vacina Pneumocócica Conjugada Heptavalente/administração & dosagem
Mastoidite/epidemiologia
Infecções Pneumocócicas/prevenção & controle
[Mh] Termos MeSH secundário: Adolescente
Proteína C-Reativa
Criança
Pré-Escolar
Serviço Hospitalar de Emergência/estatística & dados numéricos
Feminino
Hospitalização/estatística & dados numéricos
Seres Humanos
Incidência
Lactente
Israel/epidemiologia
Contagem de Leucócitos
Masculino
Mastoidite/diagnóstico
Estudos Retrospectivos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Heptavalent Pneumococcal Conjugate Vaccine); 9007-41-4 (C-Reactive Protein)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171231
[St] Status:MEDLINE


  5 / 52353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28742291
[Au] Autor:Sultan RS; Olfson M; Correll CU; Duncan EJ
[Ad] Endereço:New York State Psychiatric Institute/Department of Psychiatry, College of Physicians and Surgeons of Columbia University, 1051 Riverside Dr, New York, NY 10032. rs3511@cumc.columbia.edu.
[Ti] Título:Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring.
[So] Source:J Clin Psychiatry;78(8):e933-e939, 2017 Sep/Oct.
[Is] ISSN:1555-2101
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Concerns exist that clozapine is underutilized in the management of treatment-resistant schizophrenia. Although a 2015 change in the US Food and Drug Administration (FDA) monitoring recommendations lowered the threshold of the absolute neutrophil count for treatment interruption from 1,500/µL to 1,000/µL and removed white blood cell count thresholds from the monitoring algorithm, the implications of this policy change on clozapine interruptions remain unknown. METHODS: We analyzed outpatient prescribing records for antipsychotic medications in the Veterans Integrated Service Network 7 (VISN 7) database between 1999 and 2012 to assess the potential impact of the recent changes in FDA neutropenia monitoring recommendations on clozapine treatment discontinuation. We evaluated results of complete blood count monitoring to compare percentages of patients who developed or would have developed ≥ 1 hematologic event under the previous and current FDA guidelines in the first year following initiation of clozapine. RESULTS: From a cohort of 14,620 patients with schizophrenia (ICD-9-295.x), 246 patients received clozapine treatment (1.7%). No agranulocytosis was observed during the study period. Under the former recommendations, 5 patients in the clozapine initiation cohort (n = 160, 3.1%; 95% CI, 0.43-5.83) qualified for treatment interruption during the first year of clozapine treatment, while only 1 patient (0.6%) qualified under the current recommendations. Under the former recommendations, hematologic events occurred at a similar rate for individuals taking and not taking clozapine. CONCLUSIONS: While clozapine remains an underused medication, the new FDA monitoring guidelines are likely to substantially reduce the percentage of patients who meet criteria for clozapine-associated hematologic events requiring treatment interruption. This decrease may reduce the clinical burden of managing patients on clozapine and therefore increase the number of individuals treated with this uniquely effective medication. However, prospective studies of individuals treated under the new guidelines are needed to fully assess safety of the FDA's change.
[Mh] Termos MeSH primário: Clozapina
Monitoramento de Medicamentos
Neutropenia
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Sistemas de Notificação de Reações Adversas a Medicamentos/estatística & dados numéricos
Antipsicóticos/administração & dosagem
Antipsicóticos/efeitos adversos
Clozapina/administração & dosagem
Clozapina/efeitos adversos
Monitoramento de Medicamentos/métodos
Monitoramento de Medicamentos/estatística & dados numéricos
Prescrições de Medicamentos/estatística & dados numéricos
Feminino
Seres Humanos
Contagem de Leucócitos
Masculino
Conduta do Tratamento Medicamentoso/organização & administração
Conduta do Tratamento Medicamentoso/normas
Meia-Idade
Neutropenia/induzido quimicamente
Neutropenia/diagnóstico
Neutropenia/epidemiologia
Neutropenia/prevenção & controle
Farmacovigilância
Guias de Prática Clínica como Assunto
Escalas de Graduação Psiquiátrica
Melhoria de Qualidade
Esquizofrenia/diagnóstico
Esquizofrenia/epidemiologia
Estados Unidos/epidemiologia
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipsychotic Agents); J60AR2IKIC (Clozapine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE


  6 / 52353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28456849
[Au] Autor:Zani A; Teague WJ; Clarke SA; Haddad MJ; Khurana S; Tsang T; Nataraja RM
[Ad] Endereço:Division of General and Thoracic Surgery, The Hospital for Sick Children, 1524C-555 University Ave, Toronto, ON, M5G 1X8, Canada. augusto.zani@sickkids.ca.
[Ti] Título:Can common serum biomarkers predict complicated appendicitis in children?
[So] Source:Pediatr Surg Int;33(7):799-805, 2017 Jul.
[Is] ISSN:1437-9813
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: As appendicitis in children can be managed differently according to the severity of the disease, we investigated whether commonly used serum biomarkers on admission could distinguish between simple and complicated appendicitis. METHODS: Admission white blood cell (WBC), neutrophil (NEU), and C-reactive protein (CRP) levels were analysed by ROC curve, and Kruskal-Wallis and contingency tests. Patients were divided according to age and histology [normal appendix (NA), simple appendicitis (SA), complicated appendicitis (CA)]. RESULTS: Of 1197 children (NA = 186, SA = 685, CA = 326), 7% were <5 years, 55% 5-12, 38% 13-17. CA patients had higher CRP and WBC levels than NA and SA (p < 0.0001). NEU levels were lower in NA compared to SA or CA (p < 0.0001), but were similar between SA and CA (p = 0.6). CA patients had higher CRP and WBC levels than SA patients in 5-12- (p < 0.0001) and 13-17-year groups (p = 0.0075, p = 0.005), but not in <5-year group (p = 0.72, p = 0.81). We found CRP >40 mg/L in 58% CA and 37% SA (p < 0.0001), and WBC >15 × 10 /L in 58% CA and 43% SA (p < 0.0001). CONCLUSIONS: Admission CRP and WBC levels may help the clinician predict complicated appendicitis in children older than 5 years of age. Early distinction of appendicitis severity using these tests may guide caregivers in the preoperative decision-making process.
[Mh] Termos MeSH primário: Apendicite/diagnóstico
Proteína C-Reativa/análise
Contagem de Leucócitos
Neutrófilos/metabolismo
Índice de Gravidade de Doença
[Mh] Termos MeSH secundário: Adolescente
Apendicite/sangue
Biomarcadores/sangue
Contagem de Células
Criança
Pré-Escolar
Feminino
Seres Humanos
Masculino
Curva ROC
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Biomarkers); 9007-41-4 (C-Reactive Protein)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE
[do] DOI:10.1007/s00383-017-4088-1


  7 / 52353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29406050
[Au] Autor:Cheung CC; Constantine M; Ahmadi A; Shiau C; Chen LYC
[Ad] Endereço:Division of Hematology, Gordon and Leslie Diamond Health Care Centre, University of British Columbia, Vancouver, British Columbia, Canada.
[Ti] Título:Lymphocyte-Variant Hypereosinophilic Syndrome With Eosinophilic Myocarditis Treated With Steroids and Pegylated Interferon Alfa-2a.
[So] Source:Am J Med Sci;355(2):201-202, 2018 Feb.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Angiografia Coronária
Eletrocardiografia
Síndrome Hipereosinofílica
Interferon-alfa/administração & dosagem
Imagem por Ressonância Magnética
Miocardite
Polietilenoglicóis/administração & dosagem
Prednisona/administração & dosagem
[Mh] Termos MeSH secundário: Eosinófilos/metabolismo
Feminino
Seres Humanos
Síndrome Hipereosinofílica/sangue
Síndrome Hipereosinofílica/diagnóstico por imagem
Síndrome Hipereosinofílica/tratamento farmacológico
Síndrome Hipereosinofílica/fisiopatologia
Contagem de Leucócitos
Linfócitos/metabolismo
Meia-Idade
Miocardite/sangue
Miocardite/diagnóstico por imagem
Miocardite/tratamento farmacológico
Miocardite/fisiopatologia
Proteínas Recombinantes/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Interferon-alpha); 0 (Recombinant Proteins); 30IQX730WE (Polyethylene Glycols); Q46947FE7K (peginterferon alfa-2a); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE


  8 / 52353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29290332
[Au] Autor:Guo J; Wu M; Guo L; Zuo Q
[Ad] Endereço:Southern medical university, Nanfang hospital, department of oncology, Guangzhou, Guangdong Province, China.
[Ti] Título:Pretreatment blood neutrophil/lymphocyte ratio is associated with metastasis and predicts survival in patients with pancreatic cancer.
[So] Source:Bull Cancer;105(2):146-154, 2018 Feb.
[Is] ISSN:1769-6917
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The predictive value of systemic inflammatory markers has been explored in various types of cancer. In the present study, we aimed to investigate the association between pretreatment neutrophil/lymphocyte ratio (NLR) and tumor metastasis in pancreatic cancer, and the values of NLR as a prognostic factor of overall survival. METHODS: Clinical and laboratory data from 256 consecutive pancreatic cancer patients were analyzed retrospectively. The NLR was recorded before treatment and analyzed along with clinicopathological characteristics and overall survival of pancreatic cancer patients. RESULTS: Multivariate analysis revealed that pretreatment NLR (HR: 2.393; 95% CI: 1.326-4.320; P=0.004) was an independent risk factor for distant metastasis. Furthermore, COX regression analysis showed that in addition to pretreatment NLR (HR: 1.871; 95% CI: 1.413-2.477; P<0.001), metastasis and stage were independent prognostic factors. CONCLUSION: Pretreatment NLR values were significantly associated with distant metastasis in pancreatic cancer patients. Higher NLR values were detected in metastatic disease and may be an independent prognostic factor of overall survival in pancreatic cancer patients.
[Mh] Termos MeSH primário: Linfócitos
Neutrófilos
Neoplasias Pancreáticas/sangue
Neoplasias Pancreáticas/mortalidade
[Mh] Termos MeSH secundário: Análise de Variância
Feminino
Seres Humanos
Estimativa de Kaplan-Meier
Contagem de Leucócitos
Contagem de Linfócitos
Masculino
Meia-Idade
Neoplasias Pancreáticas/diagnóstico
Neoplasias Pancreáticas/patologia
Contagem de Plaquetas
Prognóstico
Curva ROC
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180102
[St] Status:MEDLINE


  9 / 52353 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29339102
[Au] Autor:Khafaga AF; El-Sayed YS
[Ad] Endereço:Department of Pathology, Faculty of Veterinary Medicine, Alexandria University, Edfina 22758, Egypt. Electronic address: asmaa.khafaga@alexu.edu.eg.
[Ti] Título:Spirulina ameliorates methotrexate hepatotoxicity via antioxidant, immune stimulation, and proinflammatory cytokines and apoptotic proteins modulation.
[So] Source:Life Sci;196:9-17, 2018 Mar 01.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: Methotrexate (MTX) is an efficient cytotoxic drug used against various carcinogenic, inflammatory and autoimmune diseases; however, the hepatotoxicity of MTX limits its use. Therefore, the present study aimed to evaluate the potential hepatoprotective and immune-stimulant effect of Spirulina platensis (SP) against MTX acute toxicity. MAIN METHODS: Thirty-two male Wistar rats were randomly allocated into the following four groups (n = 8): control, SP (500 mg/kg bwt, oral gavage daily for 21 days), MTX (20 mg/kg bwt, single ip injection), and MTX+SP. Hepatic and splenic histoarchitecture, leukocyte counts and serum immunoglobulins were evaluated. Hepatic oxidant/antioxidant status, proinflammatory cytokines (tumor necrosis factor-α, and interleukin 6), and pro-apoptotic proteins (caspase 3 and Bax) immunoexpression were assessed. KEY FINDINGS: MTX induced extensive hepatic necrosis and vacuolation, and sever lymphoid depletion in splenic white pulp with increased levels of serum transaminases, lactate dehydrogenase, and hepatic malondialdehyde, tumor necrosis factor-α and interleukin 6; and number of caspase 3- and Bax-positive hepatocytes. A significant decrease in leukocyte counts, serum immunoglobulins (IgA, IgM and IgG) level, and hepatic antioxidant enzymes (GSH, GPx, SOD, and CAT) was also detected. Pretreatment with SP resulted in significant improvements in hepatic and splenic histologic architecture, as well as restoring liver enzymes and reduction of lipid peroxidation product, proinflammatory cytokines, and caspase 3 and Bax immunoexpression. Additionally, a significant increase in antioxidant enzymes, serum immunoglobulins, and total leukocyte counts was demonstrated. SIGNIFICANCE: SP possesses promising antioxidant, anti-inflammatory, anti-apoptotic and immune stimulatory properties against MTX-induced hepatotoxicity and immunosuppression.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/farmacologia
Antimetabólitos/toxicidade
Antioxidantes/farmacologia
Proteínas Reguladoras de Apoptose/antagonistas & inibidores
Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle
Citocinas/antagonistas & inibidores
Metotrexato/antagonistas & inibidores
Metotrexato/toxicidade
Extratos Vegetais/farmacologia
Spirulina/química
[Mh] Termos MeSH secundário: Animais
Contagem de Leucócitos
Peroxidação de Lipídeos/efeitos dos fármacos
Masculino
Necrose
Ratos
Ratos Wistar
Baço/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antimetabolites); 0 (Antioxidants); 0 (Apoptosis Regulatory Proteins); 0 (Cytokines); 0 (Plant Extracts); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE


  10 / 52353 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29271057
[Au] Autor:Reddy JP; Hernandez M; Gunther JR; Dabaja BS; Martin GV; Jiang W; Akhtari M; Allen PK; Atkinson BJ; Smith GL; Pinnix CC; Milgrom SA; Abou Yehia Z; Osborne EM; Oki Y; Lee H; Hagemeister F; Fanale MA
[Ad] Endereço:Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
[Ti] Título:Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma.
[So] Source:Br J Haematol;180(4):545-549, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:To determine whether pre-treatment neutrophil/lymphocyte (NLR) or platelet/lymphocyte ratios (PLR) are predictive for progression in early-stage classical Hodgkin lymphoma (cHL), we derived NLR and PLR values for 338 stage I/II cHL patients and appropriate cut-off point values to define progression. Two-year freedom from progression (FFP) for patients with NLR ≥6·4 was 82·2% vs. 95·7% with NLR <6·4 (P < 0·001). Similarly, 2-year FFP was 84·3% for patients with PLR ≥266·2 vs. 96·1% with PLR <266·2 (P = 0·003). On univariate analysis, both NLR and PLR were significantly associated with worse FFP (P = 0·001). On multivariate analysis, PLR remained a significant, independent prognostic factor (P < 0·001).
[Mh] Termos MeSH primário: Plaquetas
Doença de Hodgkin/sangue
Doença de Hodgkin/mortalidade
Contagem de Leucócitos
Linfócitos
Neutrófilos
Contagem de Plaquetas
[Mh] Termos MeSH secundário: Adulto
Feminino
Doença de Hodgkin/patologia
Doença de Hodgkin/terapia
Seres Humanos
Masculino
Estadiamento de Neoplasias
Prognóstico
Modelos de Riscos Proporcionais
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171223
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15054



página 1 de 5236 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde